Please login to the form below

Not currently logged in


This page shows the latest ibrutinib news and features for those working in and with pharma, biotech and healthcare.

Roche and AbbVie prepare to move Venclexta into first-line CLL

Roche and AbbVie prepare to move Venclexta into first-line CLL

The two companies are also looking at other first-line combinations for their drugs, including combining each of them with AbbVie’s BTK inhibitor Imbruvica (ibrutinib), which was approved for

Latest news

More from news
Approximately 17 fully matching, plus 67 partially matching documents found.

Latest Intelligence

  • Taking a strategic approach Taking a strategic approach

    In the case of blood cancer drug Imbruvica (ibrutinib) - a key new product for the company - Janssen has requested its single technology appraisal for CLL and MCL be rescheduled to start

  • Pharma deals during November 2014 Pharma deals during November 2014

    Whatever CAR-T's promise, for the time being of course the chronic lymphocytic leukaemia company to beat is Pharmacyclics with Imbruvic (ibrutinib), its oral small molecule still proving remarkably resilient ... Ibrutinib blocks signals that tell

  • Pharma deals during October 2014 Pharma deals during October 2014

    This clinical trial collaboration will look at a phase 1/2 study for Opdivo in combination with Imbruvica [ibrutinib – an oral Bruton's kinase inhibitor] as a treatment option for

  • Deal Watch table for July 2013 Deal Watch table for July 2013

    Quest Diagnostics / Royalty Pharma. Purchase of royalty rights. Ibrutinib (Bruton's tyrosine kinase inhibitor) for CLL and other B-cell cancers (p3).

  • Pharma deals during July 2013 Pharma deals during July 2013

    However, Royalty Pharma did close a deal this month with presumably a fully cooperative partner, Quest Diagnostics, which had deemed the phase III anticancer drug ibrutinib to be non-core and

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
W2O Group

W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...

Latest intelligence

Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think
Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...
Peoples Award
Quality in Care Diabetes 2018: the best in innovative diabetes care
Awards highlight new evidence-based approaches to improving care...